SAN.PA - Sanofi

Paris - Paris Delayed Price. Currency in EUR
73.55
-0.22 (-0.30%)
At close: 5:36PM CET
Stock chart is not supported by your current browser
Previous Close73.77
Open73.44
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range72.79 - 73.78
52 Week Range25.06 - 87.65
Volume4,378,223
Avg. Volume6,711
Market Cap92.123B
Beta0.73
PE Ratio (TTM)10.30
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield3.30 (3.40%)
Ex-Dividend Date2017-05-16
1y Target EstN/A
  • Mylan Announces IPR Proceedings for Sanofi's Lantus Patents
    Zacksyesterday

    Mylan Announces IPR Proceedings for Sanofi's Lantus Patents

    Mylan (MYL) announced that interpartes review (IPR) proceedings has been initiated by PTAB regarding two Orange Book-listed patents, U.S. Patent Nos. 7,476,652 and 7,713,930 owned by Sanofi.

  • Alnylam Gets Some Welcome News
    Motley Fool2 days ago

    Alnylam Gets Some Welcome News

    A trial that had been on clinical hold because of a patient death has been cleared to restart.

  • Pharma Stock Roundup: Teva Announces Major Job Cuts, Lilly Provides 2018 Outlook
    Zacks2 days ago

    Pharma Stock Roundup: Teva Announces Major Job Cuts, Lilly Provides 2018 Outlook

    This week's pharma sector highlights include ASH data, Teva's restructuring announcement and Lilly's (LLY) 2018 outlook.

  • Sanofi Wants to Go It Alone -- Good Luck With That
    Bloomberg3 days ago

    Sanofi Wants to Go It Alone -- Good Luck With That

    The French drugmaker's in-house R&D efforts have been unimpressive.

  • Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?
    Motley Fool3 days ago

    Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?

    An immuno-oncology drug that's in the works could generate significant revenue growth someday.

  • Top 10 Generic Pharmaceutical Companies In 2017
    Insider Monkey4 days ago

    Top 10 Generic Pharmaceutical Companies In 2017

    The top 10 generic pharmaceutical companies in 2017 operate in the relatively recession-proof pharmaceuticals industry which is immune from the vagaries of economic cycles. The huge R&D expense and expertise required to develop new medicines is a big entry barrier and the patent laws allow pharmaceuticals companies to make monopolistic profits for a new product […]

  • Reuters4 days ago

    France's Sanofi pins hopes on new drugs after setbacks

    Sanofi's (SASY.PA) promising pipeline of experimental drugs can help it overcome setbacks including the low uptake of a new cholesterol treatment and concerns about a dengue vaccine, the French pharmaceuticals group said on Wednesday. The world's sixth largest drugmaker, battling to contain the fallout from a safety row in the Philippines over dengue vaccine Dengvaxia, said it expected to file nine medicines for regulatory assessment in the next 18 months. Shares in Sanofi were down 0.77 percent at 1510 GMT.

  • Reuters4 days ago

    France's Sanofi pins hopes on new drugs after setbacks

    Sanofi's promising pipeline of experimental drugs can help it overcome setbacks including the low uptake of a new cholesterol treatment and concerns about a dengue vaccine, the French pharmaceuticals group said on Wednesday. The world's sixth largest drugmaker, battling to contain the fallout from a safety row in the Philippines over dengue vaccine Dengvaxia, said it expected to file nine medicines for regulatory assessment in the next 18 months. Shares in Sanofi were down 0.77 percent at 1510 GMT.

  • Reuters4 days ago

    Lilly's 2018 forecast beats on strength of new drugs

    Eli Lilly and Co on Wednesday forecast 2018 profit and revenue ahead of Wall Street estimates on strong demand for recently launched drugs such as Trulicity and Taltz. Lilly said it was expecting a regulatory decision on its rheumatoid arthritis drug baricitinib, whose marketing application was initially rejected by the U.S. Food and Drug Administration. The drugmaker also expects to launch a new indication for Taltz in psoriatic arthritis.

  • Reuters4 days ago

    Sanofi CEO says M&A targets in oncology are 'very expensive'

    PARIS (Reuters) - Sanofi's Chief Executive Olivier Brandicourt on Wednesday told investors that he considered M&A targets in oncology to be "very expensive". "If you are not starting with ...

  • Reuters4 days ago

    Did Sanofi, WHO ignore warning signals on dengue vaccine?

    CHICAGO/LONDON (Reuters) - When French drugmaker Sanofi published the results of clinical trials of children given its dengue vaccine two years ago, the overall findings were that it protected against the world's biggest and fastest growing mosquito-borne disease. The study's authors cited two main possibilities: the children had immature immune systems that made the vaccine less protective, or the vaccine itself made them more susceptible to severe disease if they had never had dengue and later became infected. More than two years later, it turns out the latter was the primary factor - a revelation at the end of last month that has triggered alarm among hundreds of thousands of anxious parents in the Philippines, where the vaccine has been given to over 830,000 children.

  • Reuters4 days ago

    Did Sanofi, WHO ignore warning signals on dengue vaccine?

    CHICAGO/LONDON, Dec 12 (Reuters) - When French drugmaker Sanofi published the results of clinical trials of children given its dengue vaccine two years ago, the overall findings were that it protected against the world's biggest and fastest growing mosquito-borne disease. The study's authors cited two main possibilities: the children had immature immune systems that made the vaccine less protective, or the vaccine itself made them more susceptible to severe disease if they had never had dengue and later became infected. More than two years later, it turns out the latter was the primary factor - a revelation at the end of last month that has triggered alarm among hundreds of thousands of anxious parents in the Philippines, where the vaccine has been given to over 830,000 children.

  • TheStreet.com5 days ago

    Dengue Fever Vaccine Suspension Criticized by Drugmaker Sanofi

    French drug-maker Sanofi contends its Dengue vaccine is good for the country. After 730,000 children were vaccinated, the Philippine government stopped the program on data the drug-maker released that ...

  • Sanofi Wins FDA Approval for Biosimilar of Lilly's Humalog
    Zacks5 days ago

    Sanofi Wins FDA Approval for Biosimilar of Lilly's Humalog

    Sanofi's (SNY) Admelog, a follow-on biologic version of Lilly's Humalog, received FDA approval.

  • Reuters5 days ago

    Sanofi investors hungry for drug progress and deal news

    Sanofi (SASY.PA) still needs to convince markets it can deliver on an exciting and sustainable growth path as it contends with fresh difficulties in its vaccines arm and looks set for another gloomy year in diabetes, investors told Reuters. The French drugmaker holds an "innovation day" on Wednesday to discuss its pipeline of new drugs while it attempts to overcome fallout from a safety row in the Philippines over its dengue vaccine. Shares in Sanofi are trading close to a 10-month low and are down more than 4 percent this year after a 2.2 percent decline last year.

  • Reuters5 days ago

    Sanofi investors hungry for drug progress and deal news

    Sanofi still needs to convince markets it can deliver on an exciting and sustainable growth path as it contends with fresh difficulties in its vaccines arm and looks set for another gloomy year in diabetes, investors told Reuters. The French drugmaker holds an "innovation day" on Wednesday to discuss its pipeline of new drugs while it attempts to overcome fallout from a safety row in the Philippines over its dengue vaccine. Shares in Sanofi are trading close to a 10-month low and are down more than 4 percent this year after a 2.2 percent decline last year.

  • Reuters6 days ago

    FDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog

    The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. Admelog, generally taken just before meals, was approved for use in children older than three and adults with type 1 diabetes, as well as adults with type 2 diabetes. Like Humalog, which earned Lilly $696.2 million in the latest quarter, the short-acting drug helps diabetics control blood sugar levels after eating.

  • Reuters6 days ago

    FDA clears Sanofi's follow-on diabetes biologic of Lilly's Humalog

    The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. The drug is a short-acting ...

  • 3 High-Yield Dividend Stocks to Buy in 2018
    Motley Fool6 days ago

    3 High-Yield Dividend Stocks to Buy in 2018

    These 3 Big Pharma stocks may be worth adding to your portfolio in 2018.

  • Regeneron (REGN) Down 8.3% Since Earnings Report: Can It Rebound?
    Zacks6 days ago

    Regeneron (REGN) Down 8.3% Since Earnings Report: Can It Rebound?

    Regeneron (REGN) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Sanofi Begins Combo Studies on Multiple Myeloma Candidate
    Zacks9 days ago

    Sanofi Begins Combo Studies on Multiple Myeloma Candidate

    Sanofi (SNY) starts two new phase III studies evaluating isatuximab in combination with other cancer medicines for the treatment of multiple myeloma, a rare blood cancer.

  • Philippines wants money back from Sanofi for dengue vaccine
    Associated Press9 days ago

    Philippines wants money back from Sanofi for dengue vaccine

    MANILA, Philippines (AP) — The Philippine government will demand a refund of 3.5 billion pesos ($69.5 million) from vaccine maker Sanofi Pasteur and look at possible legal action after a study showed the vaccine used in a dengue immunization program could expose some people to severe illness, the health chief said Friday.

  • Pharma Stock Roundup: FDA Nod for NVO's Ozempic, Second Indication for Lilly's Taltz
    Zacks9 days ago

    Pharma Stock Roundup: FDA Nod for NVO's Ozempic, Second Indication for Lilly's Taltz

    FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.

  • Reuters9 days ago

    Philippines to seek refund of $59 million from Sanofi amid vaccine risk

    The Philippines will seek the return of 3 billion pesos ($59 million) it paid French drugmaker Sanofi for a dengue vaccine used to immunise hundreds of thousands of children that Sanofi has said could worsen the disease in some cases. "We will demand the refund of the 3 billion (pesos) paid for the Dengvaxia and (demand) that Sanofi set up an indemnification fund to cover the hospitalisation and medical treatment of all children who might have severe dengue," Health Secretary Francisco Duque told reporters on Friday. The Philippines last week suspended a national immunisation programme after Sanofi's recent findings that there was a risk of severe dengue occurring in previously uninfected people who were inoculated with Dengvaxia.

  • Sanofi's Pointeau on China Strategy, Partnerships
    Bloomberg Video10 days ago

    Sanofi's Pointeau on China Strategy, Partnerships

    Dec.07 -- Jean-Christophe Pointeau, China country chair at Sanofi, discusses the changes in the Chinese health market, his business strategy in China, his partnerships and the automation of the industry. He speaks on "Bloomberg Markets: Asia" from the Fortune Global Forum in Guangzhou.